MedPath

To compare the effectiveness of cabergoline and medroxyprogesterone acetate in the treatment of uterine adenomyosis

Phase 4
Conditions
Health Condition 1: N719- Inflammatory disease of uterus, unspecified
Registration Number
CTRI/2020/04/024422
Lead Sponsor
SRM College of Pharmacy
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1)age between 18-50 with complaints of chronic pelvic pain

2)USG suggestive of Adenomyosis

3)consenting to participate in the study

4) use of barrier contraception or sexual abstinence during study period.

Exclusion Criteria

1) Women attempting pregnancy or currently pregnant

2) less than six months postpartum

3)lactating mothers

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath